Marcin Bielówka

Our goal is to improve the quality of life for patients. We understand that hair loss and skin conditions can profoundly affect self-confidence and quality of life. Living with skin conditions can be challenging, which is why we are dedicated to creating effective topical dermatology treatments. We focus on improving the lives of individuals facing hair loss and chronic skin conditions, like psoriasis. At the heart of our mission is the drive to enhance quality of life through innovative treatment solutions. We aim to deliver safer, more effective therapies faster at lower cost and riskby leveraging repurposed drugs rather than through new drug development. Our dedication to research and development reflects our commitment to addressing unmet medical needs, making a tangible difference in the lives of many patients.

VAXiCAN, pre-clinical stage biotechnology company with vision to create Next Generation Immunotherapeutics, develops unique novel platform of therapeutic cancer vaccines based on proprietary enveloped virus-like particles (Enveloped VLPs), which provide the safest and most effective way of instructing and strengthening the Patients anticancer defense mechanisms. VAXiCAN VLP platform is widely supported by fully owned and in-house developed novel dedicated proprietary elements of machine learning (ML) and artificial intelligence (AI). The path chosen by the VAXiCAN is the use of naturally occurring or genetically modified oncolytic viruses using an innovative antigen delivery method using insect models (most similar solutions use mammalian, fungal or completely synthetic models). VAXiCAN VLP vaccines are designed to present the extracellular domains of cancer antigens while leveraging the immune systems mechanism to mimic viral infection, thereby enhancing antigen presentation through the recognition of pathogen-associated molecular patterns (PAMPs). This strategy not only stimulates a strong adaptive immune response characterized by the production of high-affinity antibodies and cytotoxic T cells crucial for targeting tumor cells, but also actively engages natural killer cells supported by memory cells. First pre-clinical lead candidates are addressing HER2 and GD2 cancers, incl. breast cancer, neuroblastoma, melanoma as well as HPV/HBV-related cancers with potential of at least two first-in-class drug candidates and at least one in the orphan drug and fast track regulatory designations. VAXiCAN also operates in the field of modern whole viral and protein sequencing acting as Oxford Nanopore certified partner. We specialize in bioinformatic analysis of full genomes of microorganisms, including bacteria, bacteriophages, human and animal viruses as well as full human genomes.

Pikralida is a biotechnology company that integrates research and development of innovative therapies (R&D) with Contract Research Organization (CRO) services. As a clinical-stage company, we focus on both proprietary drug development and partnered pharmaceutical research, ensuring a diversified approach that drives innovation and commercial potential. Our mission is to build a high-value portfolio of projects, ultimately leading to future licensing or strategic partnerships for global market introduction. Our flagship development program is centered around PKL-021 (marimastat), a subnanomolar matrix metalloprotease (MMP) inhibitor with broad therapeutic potential. We are advancing a pipeline of novel applications, with initial clinical-stage programs targeting: 🧠 Neuroprotection (stroke) – therapies designed to minimize long-term neurological damage and improve patient outcomes in ischemic stroke and brain injuries. ⚡ Snakebite envenoming – innovative pre-hospital treatment solutions, including an oral therapy designed to improve accessibility and survival rates in snakebite cases. Beyond these priority projects, Pikralida maintains an expanding pipeline of preclinical and early-stage programs, exploring additional indications such as diabetic retinopathy and other high-impact therapeutic areas. In addition to our own R&D pipeline, Pikralida operates as a specialized CRO, offering tailored research and development services to biotech and pharmaceutical companies. Our expertise spans across formulation development and pharmaceutical analysis 📍 Founded in Poland | 🌍 Global ambitions | 🔬 Hybrid business model | 📅 Clinical-stage company 🌐 www.pikralida.eu

We do Design Services for FPGA and ASIC! Whether you are building a complex 5G system based on FPGA or need a specialized IP-Core for DSP or cryptography, we are here!

🚀 WE BELIEVE that even the smallest entrepreneur should be able to validate his product and select marketing tactics that are effective for himself. We want to equip entrepreneurs with the ultimate future proof tactics and remove obstacles to creating businesses that have the potential to change the world. Digital First AI transforms exclusive marketing services into accessible and understandable technology. 🚀 DF.AI will recommend you the best marketing tactics based on answers to a few questions about your business. You will get access to a library of tactics where, in addition to recommendations, you will be able to view the strategies of popular brands and experienced marketers. 🚀 Sign for early access! The number of accounts for early users is limited. YOU CAN BE a part of an amazing community, dont lose your opportunity!

Laven is the first complementary health insurance in Poland, which provides certain drugs and medical devices that are not reimbursed under the basic health care of the National Health Fund. As part of the insurance, we guarantee access to selected medical technologies (MT) - innovative drugs and medical devices, and we provide treatment in the best centers in Poland - without queues and additional fees. The policy covers the purchase of a drug or medical device, organization of therapy with the use of a given medical technology and coverage of the costs of its administration. As part of the insurance, we provide access to medical e-consultation - medical consultation over the phone and Second Medical Opinion - remote consultation with the optimal treatment plan with the best specialists from leading global health centers.

We are a med-tech company that creates artificial intelligence algorithms to support doctors in diagnosing rare (hidden) diseases early based on patients medical records i.e. laboratory test results, radiology and other descriptive medical data.

W drukuje.to specjalizujemy się w usługach kompleksowego druku dla firm. Posiadamy zespół doświadczonych pracowników w bogatą wiedzę rynku poligraficznego oraz profesjonalnej obsługi klienta B2B. Naszą misją jest wdrażanie optymalizacji w całym procesie druku dla firm - od doboru odpowiedniej technologii druku, materiałów i logistyki. Wszystko po to aby zarządzanie procesem przyniosło efekty w postaci optymalizacji kosztowej oraz oszczędności czasu w postaci mniejszego zaangażowania pracowników Państwa firmy. .to realne oszczędności dla firmy .to kompleksowe usługi druku .to profesjonalna obsługa .to proste

SKY ENGINE AI is a 3D Generative AI Synthetic Data Cloud for Vision AI that generates fully annotated, synthetic data and trains vision AI algorithms at scale. The platform is architected to procedurally generate highly balanced imagery data of photorealistic environments and objects and provides advanced domain adaptation algorithms. SKY ENGINE AI platform is a tool for developers: Data Scientists, ML/Software Engineers creating computer vision projects in any industry. SKY ENGINE is #generativeAI and #visionAI company with #syntheticdata.

NeuroMedical has been funded with the main mission to develop the market and to distribute best and most innovative hi-tech medical devices. The company is divided into three main areas of expertise: Neuromodulation (core business), Spine Surgery and Diabetes Care diagnostics. Other Activities: - Clinical Trial - Clinical Training / Physicians Consulting - Regulatory Affairs - Reimbursement

Cardiomatics offers cutting-edge, cloud AI-based digital analyses of data from Holter ECGs. Our medical-grade system, based on accurate algorithms, ensure high-quality and trusted outcomes. Healthcare providers can now quickly receive an easy-to-read report and benefit from smarter diagnoses and better workflows. As a reliable partner and digital health technologies developer, Cardiomatics cooperates with physicians, manufacturers, and providers of Holter devices globally.

ARA: audience – research – analysis Badanie i analizowanie widowni – o tym jest ARA. Jest to technologia do systemowego zbierania, analizowania i agregowania danych z przestrzeni out of home, która korzysta z urządzeń pomiarowych (sensorów) i algorytmów sztucznej inteligencji. Technologia ARA działa w czasie rzeczywistym. Analizuje takie atrybuty danych istotnych dla wielkości widowni jak: ścieżki poruszania się ludzi i obiektów (samochody, tramwaje, autobusy), ich liczbę, czas pojawienia się i przebywania w zasięgu sensora, a w przypadku osób – także ich wiek i płeć. ARA pozwala na analizowanie danych z wielu punktów pomiarowych i ich korelowanie z danymi z innych systemów. SENSOR ARA Dane z ulic i innych miejsc out of home są zbierane przez sensory ARA, w które są wyposażone ekrany digital OOH lub inne formy narzędzi do komunikacji cyfrowej. Sensory to urządzenia pomiarowe połączone z centralnym systemem agregowania danych. Sensory fizycznie umożliwiają określanie takich atrybutów jak: liczba osób / obiektów, czas kontaktu z ekranem, płeć, wiek a następnie agregują wyniki i umożliwiają ich analizę. Warto wspomnieć, że wraz z rozwojem technologicznym urządzenia pomiarowe są systematycznie ulepszane, dzięki czemu rosną ich możliwości agregowania i analizowania danych. PLATFORMA ARA Wygodne narzędzie online dla użytkowników do przedstawiania i analizowania treści zebranych i zagregowanych przez sensory ARA. To miejsce prezentacji rzeczywistej liczbowej wiedzy o przebiegu kampanii DOOH: - Liczba widowni - Wiek i płeć odbiorców spotów - Liczba emisji - Czas kontaktu z kontentem reklamowym Logując się do platformy ARA sprawdzisz przebieg kampanii w czasie rzeczywistym, przeanalizujesz predykcję, wprowadzisz zmiany, wygenerujesz raport.

OpenApp Payments is a breakthrough payment app that allows for dataless checkout. The founder of OpenApp is Witold Ferenc, founder of Frisco.pl, the largest e-grocery service in Poland.

We build a unique solution for subsurface tomography based on spectral ground penetrating radar and advanced analytical software, to deliver geological information of unprecedented quality.

Altlight is new brand, specializing in the wide range of innovative and premium IoT solutions for home and office. Meet our high quality products to improve your day-to-day life.

Our goal is to improve the quality of life for patients. We understand that hair loss and skin conditions can profoundly affect self-confidence and quality of life. Living with skin conditions can be challenging, which is why we are dedicated to creating effective topical dermatology treatments. We focus on improving the lives of individuals facing hair loss and chronic skin conditions, like psoriasis. At the heart of our mission is the drive to enhance quality of life through innovative treatment solutions. We aim to deliver safer, more effective therapies faster at lower cost and riskby leveraging repurposed drugs rather than through new drug development. Our dedication to research and development reflects our commitment to addressing unmet medical needs, making a tangible difference in the lives of many patients.

VAXiCAN, pre-clinical stage biotechnology company with vision to create Next Generation Immunotherapeutics, develops unique novel platform of therapeutic cancer vaccines based on proprietary enveloped virus-like particles (Enveloped VLPs), which provide the safest and most effective way of instructing and strengthening the Patients anticancer defense mechanisms. VAXiCAN VLP platform is widely supported by fully owned and in-house developed novel dedicated proprietary elements of machine learning (ML) and artificial intelligence (AI). The path chosen by the VAXiCAN is the use of naturally occurring or genetically modified oncolytic viruses using an innovative antigen delivery method using insect models (most similar solutions use mammalian, fungal or completely synthetic models). VAXiCAN VLP vaccines are designed to present the extracellular domains of cancer antigens while leveraging the immune systems mechanism to mimic viral infection, thereby enhancing antigen presentation through the recognition of pathogen-associated molecular patterns (PAMPs). This strategy not only stimulates a strong adaptive immune response characterized by the production of high-affinity antibodies and cytotoxic T cells crucial for targeting tumor cells, but also actively engages natural killer cells supported by memory cells. First pre-clinical lead candidates are addressing HER2 and GD2 cancers, incl. breast cancer, neuroblastoma, melanoma as well as HPV/HBV-related cancers with potential of at least two first-in-class drug candidates and at least one in the orphan drug and fast track regulatory designations. VAXiCAN also operates in the field of modern whole viral and protein sequencing acting as Oxford Nanopore certified partner. We specialize in bioinformatic analysis of full genomes of microorganisms, including bacteria, bacteriophages, human and animal viruses as well as full human genomes.

Pikralida is a biotechnology company that integrates research and development of innovative therapies (R&D) with Contract Research Organization (CRO) services. As a clinical-stage company, we focus on both proprietary drug development and partnered pharmaceutical research, ensuring a diversified approach that drives innovation and commercial potential. Our mission is to build a high-value portfolio of projects, ultimately leading to future licensing or strategic partnerships for global market introduction. Our flagship development program is centered around PKL-021 (marimastat), a subnanomolar matrix metalloprotease (MMP) inhibitor with broad therapeutic potential. We are advancing a pipeline of novel applications, with initial clinical-stage programs targeting: 🧠 Neuroprotection (stroke) – therapies designed to minimize long-term neurological damage and improve patient outcomes in ischemic stroke and brain injuries. ⚡ Snakebite envenoming – innovative pre-hospital treatment solutions, including an oral therapy designed to improve accessibility and survival rates in snakebite cases. Beyond these priority projects, Pikralida maintains an expanding pipeline of preclinical and early-stage programs, exploring additional indications such as diabetic retinopathy and other high-impact therapeutic areas. In addition to our own R&D pipeline, Pikralida operates as a specialized CRO, offering tailored research and development services to biotech and pharmaceutical companies. Our expertise spans across formulation development and pharmaceutical analysis 📍 Founded in Poland | 🌍 Global ambitions | 🔬 Hybrid business model | 📅 Clinical-stage company 🌐 www.pikralida.eu

iif vc to zarządzany przez doświadczony zespół fundusz koinwestycyjny inwestujący w spółki technologiczne o globalnym potencjale oparte na silnym komponencie badawczo-rozwojowym. Dzięki współpracy z PFR Otwarte Innowacje i modelowi deal-by-deal oferuje inwestorom możliwość ko-inwestycji w wybrane spółki o ponadprzeciętnym potencjale zwrotu z inwestycji i transparentnej ścieżce wyjścia inwestycyjnego na preferencyjnych pod względem udziału w zysku warunkach.

We do Design Services for FPGA and ASIC! Whether you are building a complex 5G system based on FPGA or need a specialized IP-Core for DSP or cryptography, we are here!